Lung Cancer
Innovative ctDNA Testing Drives Progress in NSCLC Research
The TROPION-Lung12 trial uses a circulating tumor DNA assay to preoperatively screen patients with non–small cell lung cancer for eligibility in post-surgical adjuvant treatment regimens.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
FDA OKs FoundationOne Liquid CDx for Tepotinib in METex14-Skipping NSCLC
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for patients with metastatic non–small cell lung cancer with MET exon 14 skipping alterations eligible for tepotinib.
The Future of Breast Cancer Care: Blackwood on Personalized Approaches
In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
FDA Approval Sought for Dato-DXd in EGFR-Mutated NSCLC
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC
NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung cancer, with a safety profile similar to earlier studies.
